These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

100 related items for PubMed ID: 20453636

  • 1. Tissue factor pathway inhibitor polymorphisms in women with and without a history of venous thrombosis and the effects of postmenopausal hormone therapy.
    Opstad TB, Eilertsen AL, Høibraaten E, Skretting G, Sandset PM.
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):516-21. PubMed ID: 20453636
    [Abstract] [Full Text] [Related]

  • 2. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
    Lincz LF, Adams MJ, Scorgie FE, Thom J, Baker RI, Seldon M.
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
    [Abstract] [Full Text] [Related]

  • 3. Analysis of a T-287C polymorphism in the tissue factor pathway inhibitor gene and identification of a repressor element in the promoter.
    Amini Nekoo A, Iles D.
    Thromb Res; 2008 Sep; 121(6):813-9. PubMed ID: 17931693
    [Abstract] [Full Text] [Related]

  • 4. Functional characterization of polymorphisms in the human TFPI gene.
    Skretting G, Stavik B, Landvik NE, Myklebust CF, Iversen N, Zienolddiny S, Sandset PM.
    Biochem Biophys Res Commun; 2010 Jun 18; 397(1):106-11. PubMed ID: 20519147
    [Abstract] [Full Text] [Related]

  • 5. The -33T-->C polymorphism in intron 7 of the TFPI gene influences the risk of venous thromboembolism, independently of the factor V Leiden and prothrombin mutations.
    Ameziane N, Seguin C, Borgel D, Fumeron F, Moatti D, Alhenc-Gelas M, Grandchamp B, Aiach M, Emmerich J, de Prost D.
    Thromb Haemost; 2002 Aug 18; 88(2):195-9. PubMed ID: 12195688
    [Abstract] [Full Text] [Related]

  • 6. Polymorphisms in antithrombin and in tissue factor pathway inhibitor genes are associated with recurrent pregnancy loss.
    Guerra-Shinohara EM, Bertinato JF, Tosin Bueno C, Cordeiro da Silva K, Burlacchini de Carvalho MH, Pulcineli Vieira Francisco R, Zugaib M, Cerda A, Morelli VM.
    Thromb Haemost; 2012 Oct 18; 108(4):693-700. PubMed ID: 22918506
    [Abstract] [Full Text] [Related]

  • 7. Association of Asn221Ser mutation in tissue factor pathway inhibitor-beta with plasma total tissue factor pathway inhibitor level.
    Ishikawa J, Okada H, Kato H, Takeshita S, Honda S, Kawasaki T, Suehisa E, Tsuji H, Madoiwa S, Sakata Y, Kojima T, Murata M, Ikeda Y, Kokubo Y, Okamura T, Tomoike H, Miyata T.
    Blood Coagul Fibrinolysis; 2009 Jan 18; 20(1):22-6. PubMed ID: 20523161
    [Abstract] [Full Text] [Related]

  • 8. The 536C-->T transition in the human tissue factor pathway inhibitor (TFPI) gene is statistically associated with a higher risk for venous thrombosis.
    Kleesiek K, Schmidt M, Götting C, Schwenz B, Lange S, Müller-Berghaus G, Brinkmann T, Prohaska W.
    Thromb Haemost; 1999 Jul 18; 82(1):1-5. PubMed ID: 10456444
    [Abstract] [Full Text] [Related]

  • 9. Association of genetic polymorphisms with plasma TFPI level: Boon or curse for DVT patients - Study from India.
    Kamal K, Amit S, Kanwaljeet S, Ravi R, Hareram P, Ravi K, Kumar KV, Pravas M, Renu S.
    Blood Cells Mol Dis; 2017 Jul 18; 66():31-36. PubMed ID: 28810169
    [Abstract] [Full Text] [Related]

  • 10. Polymorphisms in the protein C gene as risk factor for venous thrombosis.
    Pomp ER, Doggen CJ, Vos HL, Reitsma PH, Rosendaal FR.
    Thromb Haemost; 2009 Jan 18; 101(1):62-7. PubMed ID: 19132190
    [Abstract] [Full Text] [Related]

  • 11. A new T-287C polymorphism in the 5' regulatory region of the tissue factor pathway inhibitor gene. Association study of the T-287C and C-399T polymorphisms with coronary artery disease and plasma TFPI levels.
    Moatti D, Haidar B, Fumeron F, Gauci L, Boudvillain O, Seknadji P, Olliver V, Aumont MC, de Prost D.
    Thromb Haemost; 2000 Aug 18; 84(2):244-9. PubMed ID: 10959696
    [Abstract] [Full Text] [Related]

  • 12. [Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].
    Zhang XL, Zhu J, Chen WH, Zhai ZG, Zhang YH.
    Zhonghua Yi Xue Za Zhi; 2018 Mar 27; 98(12):901-906. PubMed ID: 29665662
    [Abstract] [Full Text] [Related]

  • 13. A locus on chromosome 2 influences levels of tissue factor pathway inhibitor: results from the GAIT study.
    Almasy L, Soria JM, Souto JC, Warren DM, Buil A, Borrell M, Muñoz X, Sala N, Lathrop M, Fontcuberta J, Blangero J.
    Arterioscler Thromb Vasc Biol; 2005 Jul 27; 25(7):1489-92. PubMed ID: 15845911
    [Abstract] [Full Text] [Related]

  • 14. Tissue factor pathway inhibitor relates to fibrin degradation in patients with acute deep venous thrombosis.
    Sidelmann JJ, Bladbjerg EM, Gram J, Münster AM, Jespersen J.
    Blood Coagul Fibrinolysis; 2008 Jul 27; 19(5):405-9. PubMed ID: 18600090
    [Abstract] [Full Text] [Related]

  • 15. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E, Qvigstad E, Andersen TO, Mowinckel MC, Sandset PM.
    Thromb Haemost; 2001 May 27; 85(5):775-81. PubMed ID: 11372667
    [Abstract] [Full Text] [Related]

  • 16. Catechol-O-methyltransferase genotype is associated with plasma total homocysteine levels and may increase venous thrombosis risk.
    Gellekink H, Muntjewerff JW, Vermeulen SH, Hermus AR, Blom HJ, den Heijer M.
    Thromb Haemost; 2007 Dec 27; 98(6):1226-31. PubMed ID: 18064318
    [Abstract] [Full Text] [Related]

  • 17. Association between estrogen receptor alpha and beta gene polymorphisms and deep vein thrombosis.
    Aléssio AM, Höehr NF, Siqueira LH, Ozelo MC, de Pádua Mansur A, Annichino-Bizzacchi JM.
    Thromb Res; 2007 Dec 27; 120(5):639-45. PubMed ID: 17184825
    [Abstract] [Full Text] [Related]

  • 18. Effect of long-term hormone replacement therapy on tissue factor pathway inhibitor and thrombin activatable fibrinolysis inhibitor in healthy postmenopausal women: a randomized controlled study.
    Bladbjerg EM, Madsen JS, Kristensen SR, Abrahamsen B, Brixen K, Mosekilde L, Jespersen J.
    J Thromb Haemost; 2003 Jun 27; 1(6):1208-14. PubMed ID: 12871321
    [Abstract] [Full Text] [Related]

  • 19. Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population.
    Hoppe B, Tolou F, Dörner T, Kiesewetter H, Salama A.
    Thromb Haemost; 2006 Oct 27; 96(4):465-70. PubMed ID: 17003923
    [Abstract] [Full Text] [Related]

  • 20. Low levels of heparin-releasable tissue factor pathway inhibitor in young patients with thrombosis.
    Ariëns RA, Alberio G, Moia M, Mannucci PM.
    Thromb Haemost; 1999 Feb 27; 81(2):203-7. PubMed ID: 10063992
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.